Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

Omalizumab may cause hair loss.

This study confirmed omalizumab's safety but noted that hair loss was more prevalent than previously reported, with side effects influencing treatment decisions especially in patients with reduced medication effectiveness.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

This study observed that omalizumab may induce alopecia, particularly in females aged 18-60, though establishing a direct cause-effect link remains challenging. Alopecia areata was noted as a possible uncommon, yet transient, hair loss type associated with omalizumab.

This study reviewed the dosages of products approved in Japan from 2003-2010 and found that 28.1% were at different levels than in the U.S., with limited evidence suggesting different clinical responses.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

In this case report, two cats with asthma developed localized skin lesions associated with inhalant glucocorticoid use, which resolved after adjusting treatment and administering milbemycin.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

This study identified recurrent dry cough, wheezing, and respiratory discomfort as key symptoms valued in early asthma diagnosis among children aged 5 to 12.

In this study, researchers investigated the role of the ATX-LPA axis in asthma pathogenesis using human and mouse models and highlighted the potential for developing new ATX inhibitors as effective asthma treatments.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

This study found that inhaled fluticasone for 11 months did not adversely affect the immune function or response to vaccination in horses with heaves.

This case study reports a successful use of co-trimoxazole in treating a 13-year-old girl with symptoms suggestive of autoimmune disorders and relapsing polychondritis.

This article reviews topics from the American Academy of Veterinary Dermatology and American College of Veterinary Dermatology Annual Meeting and contains no new clinical findings.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

In this case report, researchers described a German Spitz dog with alopecia X, emphasizing successful hair regrowth with deslorelin treatment, highlighting its efficacy as a therapeutic option and the necessity for accurate diagnosis in veterinary dermatology.

In this study, researchers found that a single oral dose of afoxolaner was safe and effective in treating a severe case of Trixacarus caviae mange in a guinea pig, achieving full remission of clinical signs and mite eradication within 4 weeks without needing repeated treatment.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.